To Focus on Investor Relations and Global Business Development As iNtRON Biotechnology (hereafter “iNtRON”) has grown up steadily, iNtRON has opened a new Seoul Office in the center of Seoul with great accessibility to focus on global business and investor relations. iNtRON is developing novel...
“Nightmare bacteria” with the power to resist most antibiotics are popping up across the U.S., but new, aggressive policies can help stop them from spreading, federal health officials said Tuesday. A new program for testing suspect bacteria turned up unusual antibiotic-resistance genes 221 times in...
In January 2018, The Catholic University of Korea’s Division of Infectious Disease released a paper on the subject of seriousness of multidrug-resistant organisms (MDROs) and suggested control methods to prevent bacterial epidemic disease occurrence. Seriousness of MDROs MDROs including Carbapenem resistance bacteria or well known...
Geneva, 18 January 2018 – The AMR Industry Alliance launches its first report that shows the commitment of the life sciences industry to tackle the public health threat of antimicrobial resistance (AMR). The Alliance brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies...
iNtRON Biotechnology held SAL200’s Phase 1b MAD study initiation meeting at Seoul National University Hospital on January 16th, 2018. Designated clinical research center, Seoul National University’s professors, doctors, nurses and other related participants to this study attended the meeting, and discussed detailed study process and...
iNtRON Biotechnology has been conducting evaluation tests on the recombinant phage endolysins AP50-31 and LysB4, to validate their bacteriolytic properties against Bacillus genus. As a result, AP50-31 and LysB4 displayed rapid bacteriolytic activity against broad spectrum of Bacillus genus including Bacillus anthracis strains, and...